Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
2006/08/11 by Heiko Braak, Irina Alafuzoff, Thomas Arzberger +2 · 66 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Alzheimer's disease research and treatments #S100 Proteins and Annexins #Gene expression and cancer classification
paper · pdf · doi:10.1007/s00401-006-0127-z
Abstract
Assessment of Alzheimer's disease (AD)-related neurofibrillary pathology requires a procedure that permits a sufficient differentiation between initial, intermediate, and late stages. The gradual deposition of a hyperphosphorylated tau protein within select neuronal types in specific nuclei or areas is central to the disease process. The staging of AD-related neurofibrillary pathology originally described in 1991 was performed on unconventionally thick sections (100 mum) using a modern silver technique and reflected the progress of the disease process based chiefly on the topographic expansion of the lesions. To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections (5-15 mum) and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis. It is anticipated that this revised methodological protocol will enable a more uniform application of the staging procedure.
Citations
Cited by
- Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons
- Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
- Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study
- Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer’s disease
- Molecular pathology of neurodegenerative diseases: principles and practice
- Assessing individual variability of the entorhinal subfields in health and disease
- Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
- Characteristics of Dyshoric Capillary Cerebral Amyloid Angiopathy
- Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
- The Revised National Alzheimer’s Coordinating Center’s Neuropathology Form—Available Data and New Analyses
- Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations
- Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
- Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease
- Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes
- Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
- MCR-VQGAN: A Scalable and Cost-Effective Tau PET Synthesis Approach for Alzheimer's Disease Imaging
- Folic acid prevents habituation memory impairment and oxidative stress in an aging model induced by D-galactose
- Rapid Eye Movement Sleep Behavior Disorder with Clinical Dementia with Lewy Bodies Phenotype but Lacking Postmortem Central Nervous System Synuclein Pathology: Alternate Etiologies
- Pragmatic algorithm for visual assessment of 4-Repeat tauopathies in [18F]PI-2620 PET Scans
- A Multicollinearity-Aware Signal-Processing Framework for Cross-β Identification via X-ray Scattering of Alzheimer's Tissue
- Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease
- Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
- Aging and Alzheimer's disease pathology
- Accumulation of phosphorylated TDP‐43 in the cytoplasm of Schwann cells in a case of sporadic amyotrophic lateral sclerosis
- Corticobasal degeneration with visual hallucination as an initial symptom: A case report
- Pattern separation and pattern completion in Alzheimer's disease: Evidence of rapid forgetting in amnestic mild cognitive impairment
- A lifespan staging model of basal forebrain cholinergic vulnerability
- 3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale x‐ray phase‐contrast tomography
- β-Amyloid induces microglial expression of GPC4 and APOE leading to increased neuronal tau pathology and toxicity
- Endothelial Cells Are Heterogeneous in Different Brain Regions and Are Dramatically Altered in Alzheimer's Disease
- β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brain
- A central role for acetylcholine in entorhinal cortex function and dysfunction with age in humans and mice
- Characterizing the MRI signature of hippocampal sclerosis of aging
- Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease
- Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
- The chaperones HSP90AA1, HSP90AB1 and BAG3 are specifically distributed among human hippocampal subfields during different Alzheimer's disease stages
- Morphological and Hyperphosphorylation Transitions of Nanoscale Tau Aggregates in Alzheimer's Disease
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
- Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. [europepmc]
- Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. [europepmc]
- Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. [europepmc]
- Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. [europepmc]
- Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? [europepmc]
- Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. [europepmc]
- A pathophysiological framework of hippocampal dysfunction in ageing and disease. [europepmc]
- Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. [europepmc]
- National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. [europepmc]
- National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. [europepmc]
- Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. [europepmc]
- Primary age-related tauopathy (PART): a common pathology associated with human aging. [europepmc]
- The evolution of preclinical Alzheimer's disease: implications for prevention trials. [europepmc]
- Spreading of pathology in neurodegenerative diseases: a focus on human studies. [europepmc]
- Tau positron emission tomographic imaging in aging and early Alzheimer disease. [europepmc]
- Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. [europepmc]
- PET Imaging of Tau Deposition in the Aging Human Brain. [europepmc]
- Tau-targeting therapies for Alzheimer disease. [europepmc]
- Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. [europepmc]
- Protein transmission in neurodegenerative disease. [europepmc]
- Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. [europepmc]
- Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. [europepmc]
- Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. [europepmc]
- Four distinct trajectories of tau deposition identified in Alzheimer's disease. [europepmc]
- Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. [europepmc]
Related